Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NC318 with Chemotherapy in Advanced NSCLC
NCT04430933Phase 2Withdrawn
- Sponsor
- NextCure, Inc.
- Start
- Dec 2021
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of nc318 in non-small cell lung cancer (NSCLC), sponsored by NextCure, Inc.. Planned start Dec 2021; status: withdrawn.
02
Drugs
nc318
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04430933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04430933.